A new urine-based test improved prostate cancer detection – including detecting more aggressive forms of prostate cancer – compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds.
Researchers have developed and tested a new tool that searches for the most common genetic anomalies seen in cancer. The assay demonstrates the ability to make gene sequencing easier over a large volume of samples. In the future, this may mean that patients would not always need to undergo a fresh biopsy in order to identify a potential treatment strategy, as is currently necessary with more comprehensive sequencing approaches.
More patients age 9-26 started and completed cervical cancer vaccine series due to electronic health record “prompts” at doctor appointments.
In certain types of cancer, nerves and cancer cells enter an often lethal and intricate waltz where cancer cells and nerves move toward one another and eventually engage in such a way that the cancer cells enter the nerves.
Lisa A. Newman, M.D., M.P.H., director of the Breast Care Center, is one of seven University of Michigan faculty members to receive the 2015 Harold R. Johnson Diversity Service Award from the Office of the Provost.
Research has identified a gene critical to controlling the body’s ability to create blood cells and immune cells from blood-forming stem cells, a process critical during bone marrow transplant.
One of Ann Arbor’s most exciting educational events is back. One Day Closer gives individuals and families an up-close look at one of the world’s leading cancer research facilities and what its internationally-recognized scientists and colleagues are doing to discover the cure for cancer.
University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer.
A new study finds that many women diagnosed with breast cancer are concerned about the genetic risk of developing other cancers themselves or of a loved one developing cancer.
Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.